| scholarly article | Q13442814 |
| P50 | author | Jack Cuzick | Q21005493 |
| Ivana Sestak | Q42801190 | ||
| P2860 | cites work | Serum lipids, lipid-lowering drugs, and the risk of breast cancer | Q46772398 |
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial | Q46847543 | ||
| Exemestane for breast-cancer prevention in postmenopausal women | Q48657440 | ||
| Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 | Q58466062 | ||
| Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study | Q59288218 | ||
| Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 | Q61192532 | ||
| Calculation of population attributable risk for alcohol and breast cancer (United States) | Q61997519 | ||
| Tamoxifen and contralateral breast cancer | Q69867231 | ||
| The prevention of breast cancer | Q69874879 | ||
| Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial | Q79803594 | ||
| Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors | Q25257303 | ||
| Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer | Q25257496 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation | Q28137833 | ||
| COX inhibitors and breast cancer | Q28194592 | ||
| Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial | Q28244429 | ||
| Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women | Q28251695 | ||
| Lasofoxifene in postmenopausal women with osteoporosis | Q28274186 | ||
| Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial | Q28277066 | ||
| Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study | Q28281843 | ||
| Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial | Q28289262 | ||
| Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy | Q28300092 | ||
| The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women | Q29396434 | ||
| Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q29619251 | ||
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | Q34382805 | ||
| Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial | Q34440858 | ||
| Overview of the main outcomes in breast-cancer prevention trials | Q35057371 | ||
| Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer | Q36924504 | ||
| Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study | Q42540931 | ||
| Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen | Q43233449 | ||
| Tamoxifen for breast cancer among hysterectomised women | Q43953925 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial | Q44146948 | ||
| A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer | Q44613177 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda | Q44635849 | ||
| A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer | Q44795543 | ||
| Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene | Q45168977 | ||
| Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women | Q46315785 | ||
| Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial | Q46595222 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 568-573 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | Preventive therapy for breast cancer. | |
| P478 | volume | 14 |
| Q36792134 | Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk |
| Q33698278 | Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer |
| Q35179515 | Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer |
Search more.